Cassava Sciences | PTIE - Current Assets


Cassava Sciences reported $87.96M in Current Assets for its fiscal quarter ending in March of 2026.





Current Assets Change Date
Abbott USD 25.51B 488M Mar/2026
Amgen USD 34.96B 3.49B Jun/2026
Biogen USD 7.31B 1.88B Jun/2026
Cara Therapeutics USD 25.33M 6.21M Mar/2026
Cassava Sciences USD 87.96M 9.74M Mar/2026
Eisai JPY 883.01B 121.38B Jun/2026
Eli Lilly USD 64.67B 9.84B Jun/2026
Geron USD 486.34M 12.19M Jun/2026
J&J USD 59.77B 601M Jun/2026
Merck USD 36.68B 1.66B Jun/2026
Novartis USD 27.35B 744M Jun/2026
Novavax USD 771.1M 79.72M Jun/2026
Pfizer USD 41.36B 1.46B Jun/2026
Roche Holding CHF 35.44B 3.29B Jun/2026